Of donors, 59% were male, 38% AA and 24% aged over 60 years. Survival analysis: 83 patients died over a median follow up of 58.5 months (95% CI: 46.5-67.3, mean survival 110.4 months. Fourteen patients underwent re-transplantation. Mean time to graft failure = 84.3
months, median follow-up = 59 months, 95 % CI (48.2, 68.3). DRI was significantly associated with patient death (ρ=0.04) but not second LT. 〇f 104 patients who had at least one post-LT LBx demonstrating F0/F1 fibrosis, 70 progressed to >F2 (median time to progression from LT: 31.3 months, median follow up 81.5 months). On multivariate analysis, significant donor-specific predictors of fibrosis progression were: donor age > 60 years, donation after Tanespimycin in vitro cardiac death (DCD), race mismatch: white donor/ black recipient. DRI significantly correlated with fibrosis progression (p= 0.03, HR 1.97). Conclusions: 1.Fibrosis progression in HCV infected LT recipients is strongly associated with donor characteristics: specifically donor age, DCD criteria and race mismatch. 2.DRI, an objective measure of donor quality, appears to correlate both with rate of histological progression and overall survival. Disclosures: Kirti Shetty – Grant/Research
Support: Ikaria, Novartis, Onyx-Bayer, Hyperion; Speaking and Teaching: LBH589 chemical structure Merck-Schering Plough, Salix, Gilead, Onyx The following people have nothing to disclose: Chris J. Maxwell, Sameer Desale, Bhaskar Kallakury, Elizabeth Landry, Jonathan C. Julia, Jacqueline Laurin, Rohit Satoskar, Thomas Fishbein INTRODUCTION PVT may increase the complexity
of the LT surgery and may even preclude LT. Whether specific disease or recipient factors present a higher risk of PVT in LT recipients is unknown. METHODS All adult primary LT recipients between 3/1/02-12/31/11 from the UNOS-OPTN database were included. PVT status was available on 97% of LT recipients. We defined probable NASH (PN) as cryptogenic cirrhosis + diabetes (DM), hypertension, or BMI>40; NASH/PN was analyzed Smoothened as one group. RESULTS Prevalence of PVT at LT increased from 3% in 2002 to 10% in 2011.〇 f 41, 036 LT recipients (31% female, 73% white, median age 55 yrs), 2569 (6%) had PVT at LT, 1765 (69%) of whom did not have PVT at time of LT listing. Patients (pts) with PVT were older, more often male, had NASH, DM, and less often had HCV. MELD at LT and HCC prevalence were similar between pts with and without PVT. Independent predictors of PVT at LT were older age, Hispanic race, previous abdominal surgery, TIPS, listing BMI, DM and NASH (multivariable 〇R 1.55, p<0.001; Table). Female gender and black race were associated with decreased risk of PVT. While PVT was more common in pts with DM+NASH than DM+non-NASH (11% vs 7%, p<0.001), there was no interaction between NASH and DM. The association between NASH and PVT persisted in pts with BMI<30 (OR 1.25, p=0.04), but was attenuated in non-DM pts (〇R 1.15, p=0.19).